Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers
Other than optimizing medical management of cardiac risk factors, and reducing radiotherapy (RT) dose to the heart, there currently exist no interventions to mitigate or reverse the adverse cardiac effects of RT. Aerobic exercise has been demonstrated to improve patient quality of life, cardiac outcomes, and cardiorespiratory fitness in patients with cancer receiving cardiotoxic systemic therapies, but the effects of aerobic exercise on patients at high risk for radiation induced heart disease (RIHD) is unknown. In addition, home-based cardiac rehabilitation has not been tested in patients with thoracic cancers.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Jul 12, 2024 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Supportive Care
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Washington University School of Medicine
- Interventions being studied
- Procedure: Home-based cardiac rehabilitation
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Pathologically confirmed or radiographically diagnosed non-small cell lung cancer, small cell lung cancer, esophageal cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, sarcoma, thymoma, or left-sided breast cancer.
- Planning to receive neo-adjuvant, adjuvant, or definitive radiation therapy to the thorax with curative intent.
- Willing to participate in home-based cardiac rehabilitation program and be monitored remotely via smart phone application
- Possess a smart phone or tablet capable of supporting teleHeart application
- Willing and eligible to co-enroll in the Cardiovascular Toxicity in Cancer and Improvement in Recovery (SURVIVE) Registry Study (HRPO# 201801031).
- At least 18 years of age.
- ECOG performance status ≤ 2
- Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).
- Presence of distant metastatic disease (except patients with lymphoma).
- Life expectancy less than 6 months
- Patient lives in skilled nursing facility, chronic care facility, nursing home, or palliative care or hospice facility
- Unable to walk
- Presence of significant cancer disease burden that would make patient unlikely to tolerate cardiac rehabilitation (CR)
- Diagnosis of primary cervical esophageal cancer.
- Presence of unstable angina.
- Recipient of heart transplant.
- Patient on cardiac transplant list or has a ventricular assist device
- Patient's baseline weight \> 300 lbs (due to weight limitations of the scale and bioelectrical impedance device)
- Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.
- Other medical comorbidities that make the patient unable to participate in the CR program or other assessments involved with this study.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Washington University School of MedicineSt Louis, Missouri
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 12, 2024. Always confirm current availability with the study team.